Margarette C. Mariano

Margarette C. Mariano

Auto-generated profile, based on publicly available information

Margarette C. Mariano

Department of Biochemistry

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
HYHyun Ah Yoon
Hyun Ah Yoon
RBRachel Bartash
Rachel Bartash
IGInessa Gendlina
Inessa Gendlina
JRJohanna Rivera
Johanna Rivera
ANAntonio Nakouzi
Antonio Nakouzi
LPLiise-Anne Pirofski
Liise-Anne Pirofski
Convalescent plasma with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) antibodies (CCP) may hold promise as a treatment for coronavirus disease 2019 (COVID-19). We compared the mortality and clinical outcome of patients with COVID-19 who received 200 mL of CCP with a spike protein IgG titer ≥ 1:2430 (median 1:47,385) within 72 hours of admission with propensity score–matched controls cared for at a medical center in the Bronx, between April 13 and May 4, 2020. Matching criteria for controls were age, sex, body mass index, race, ethnicity, comorbidities, week of admission, oxygen requirement, D-dimer, lymphocyte counts, corticosteroid use, and anticoagulation use. There was no difference in mortality or oxygenation between CCP recipients and controls at day 28. When stratified by age, compared with matched controls, CCP recipients less than 65 years had 4-fold lower risk of mortality and 4-fold lower risk of deterioration in oxygenation or mortality at day 28. For CCP recipients, pretransfusion spike protein IgG, IgM, and IgA titers were associated with mortality at day 28 in univariate analyses. No adverse effects of CCP were observed. Our results suggest CCP may be beneficial for hospitalized patients less than 65 years, but data from controlled trials are needed to validate this finding and establish the effect of aging on CCP efficacy.

18 January 2022 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
GLGorka Lasso
Gorka Lasso
SKSaad Khan
Saad Khan
SAStephanie A. Allen
Stephanie A. Allen
MMMargarette Mariano
Margarette Mariano
CFCatalina Florez
Catalina Florez
OVOlivia Vergnolle
Olivia Vergnolle
The clinical outcome of SARS-CoV-2 infection varies widely between individuals. Machine learning models can support decision making in healthcare by assessing fatality risk in patients that do not yet show severe signs of COVID-19. Most predictive models rely on static demographic features and clinical values obtained upon hospitalization. However, time-dependent biomarkers associated with COVID-19 severity, such as antibody titers, can substantially contribute to the development of more accurate outcome models. Here we show that models trained on immune biomarkers, longitudinally monitored throughout hospitalization, predicted mortality and were more accurate than models based on demographic and clinical data upon hospital admission. Our best-performing predictive models were based on the temporal analysis of anti-SARS-CoV-2 Spike IgG titers, white blood cell (WBC), neutrophil and lymphocyte counts. These biomarkers, together with C-reactive protein and blood urea nitrogen levels, were found to correlate with severity of disease and mortality in a time-dependent manner. Shapley additive explanations of our model revealed the higher predictive value of day post-symptom onset (PSO) as hospitalization progresses and showed how immune biomarkers contribute to predict mortality. In sum, we demonstrate that the kinetics of immune biomarkers can inform clinical models to serve as a powerful monitoring tool for predicting fatality risk in hospitalized COVID-19 patients, underscoring the importance of contextualizing clinical parameters according to their time post-symptom onset.

4 December 2020 in medRxiv
Verified
Preprint
Open access
PDF file
HYHyun Ah Yoon
Hyun Ah Yoon
RBRachel Bartash
Rachel Bartash
IGInessa Gendlina
Inessa Gendlina
JRJohanna Rivera
Johanna Rivera
ANAntonio Nakouzi
Antonio Nakouzi
LPLiise-Anne Pirofski
Liise-Anne Pirofski
Convalescent plasma with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) antibodies (CCP) may hold promise as treatment for Coronavirus Disease 2019 (COVID-19). We compared the mortality and clinical outcome of patients with COVID-19 who received 200mL of CCP with a Spike protein IgG titer ≥1:2,430 (median 1:47,385) within 72 hours of admission to propensity score-matched controls cared for at a medical center in the Bronx, between April 13 to May 4, 2020. Matching criteria for controls were age, sex, body mass index, race, ethnicity, comorbidities, week of admission, oxygen requirement, D-dimer, lymphocyte counts, corticosteroids, and anticoagulation use. There was no difference in mortality or oxygenation between CCP recipients and controls at day 28. When stratified by age, compared to matched controls, CCP recipients <65 years had 4-fold lower mortality and 4-fold lower deterioration in oxygenation or mortality at day 28. For CCP recipients, pre-transfusion Spike protein IgG, IgM and IgA titers were associated with mortality at day 28 in univariate analyses. No adverse effects of CCP were observed. Our results suggest CCP may be beneficial for hospitalized patients <65 years, but data from controlled trials is needed to validate this finding and establish the effect of ageing on CCP efficacy.

13 October 2025 in ACS Infectious Diseases
Verified
Journal Article
Closed access
KRKevin E. Ramos
Kevin E. Ramos
MMMargarette C. Mariano
Margarette C. Mariano
EMEva Mittler
Eva Mittler
RPRomina Pardo
Romina Pardo
VZVanessa Zylberman
Vanessa Zylberman
JLJonathan R. Lai
Jonathan R. Lai

23 August 2025 in ACS Chemical Biology
Verified
Journal Article
Closed access
MMMargarette C. Mariano
Margarette C. Mariano
MHMatthew Gregory Hvasta
Matthew Gregory Hvasta
KDKimberly A. Dowd
Kimberly A. Dowd
WHWei-Chiao Huang
Wei-Chiao Huang
HJHelen S. Jung
Helen S. Jung
JLJonathan R. Lai
Jonathan R. Lai

29 November 2018 in Blood
Verified
Journal Article
Open access
IFIan Ferguson
Ian Ferguson
CLChristine Lam
Christine Lam
MMMargarette C. Mariano
Margarette C. Mariano
DWDonghui Wang
Donghui Wang
PPPaul Phojanakong
Paul Phojanakong
AWArun P. Wiita
Arun P. Wiita
Introduction: Clinical efficacy of proteasome inhibitors (PIs) has established multiple myeloma (MM) as the paradigm cancer type in which to therapeutically target protein homeostasis. However, PI resistance is one of the key clinical challenges in this disease. While mechanisms of PI resistance appear complex, proteomic analysis showed multiple heat shock proteins to be highly upregulated in PI-resistant cell line models (Soriano et al, Leukemia (2016) 30:2198). Furthermore, HSPA1B, which encodes a cytosolic Hsp70, is one of the genes which best-stratifies PI-sensitive versus resistant MM cell lines (Mitra et al, Blood Cancer J (2017) 7:e581). These findings support the hypothesis that Hsp70 family chaperones may be critical in maintaining plasma cell protein homeostasis by reducing unfolded protein burden in the PI-refractory setting, indicating potential as a therapeutic target. Targeting Hsp70 may also therefore be effective in combination with PIs or other agents targeting MM protein homeostasis. Here, we profiled a series of novel, allosteric Hsp70 inhibitors of the "JG" class (Shao et al, J Med Chem (2018) 61:6163). We aimed to evaluate their role as anti-myeloma therapeutics as well as their utility as tool compounds to better define targetable protein homeostasis networks in MM. Methods: "JG" compounds were screened in quadruplicate against a panel of 13 cell lines: 9 MM, one AML, 3 immortalized normal bone marrow stromal, in 384-well plates with viability measured by CellTiter-Glo. The parental compound JG98 was tested in combination with the p97 inhibitor CB-5083, the PI bortezomib, and Hsp90 inhibitor 17-DMAG in RPMI-8226, MM1.S, KMS34, HS5, and CMK cell lines for 72 hours, with synergy and antagonism quantified using the ZIP score method. Murine studies were performed using luciferase-labeled RPMI-8226 implanted in NOD scid gamma (NSG) mice (n = 5 mice per arm). For cell surface mass spectrometry experiments, RPMI-8226 and AMO-1 cells were treated with JG342 at the LD20 for 48 hours prior to biotinylation of cell surface glycoproteins (n=3), followed by enrichment for biotinylated proteins with Neutravidin beads and LC-MS sample processing and analysis. For pulsed-SILAC experiments (n = 2), MM1.S cells were grown in light medium for six doublings, followed by exchange to heavy medium (Arg10 and Lys8) with JG342 treatment at the LD10 or DMSO, with timepoint collections performed at 16, 21, and 26 hours, followed by sample processing and LC-MS analysis. All mass spectrometry data was analyzed in MaxQuant and statistical analysis was performed in Perseus and R. Results: Supporting our hypothesis, drug screening of 16 JG compounds revealed consistently greater potency versus a PI-resistant AMO-1 cell line versus the parental line (Fig. A). We focused on the lead compound JG342, which exhibits sub-µM LC50s (140-500 nM) against a panel of myeloma cell lines and a favorable therapeutic index against bone marrow stromal cells. However, all tested JG molecules, including JG342, showed unfavorable pharmacokinetics in NSG mouse models and could not demonstrate in vivo anti-MM efficacy at achievable doses. Therefore, we focused on JG molecules as tool compounds to probe protein homeostasis in MM and further validate Hsp70 as a therapeutic target in this disease. Combination assays using JG98, bortezomib, CB-5083, and 17-DMAG revealed surprisingly diverse, cell line-specific protein homeostasis wiring networks leading to differential synergism and antagonism in dual therapies targeting the proteostasis machinery. To evaluate potential combination effects of Hsp70 inhibition with immunotherapies, we employed cell surface proteomics and found that JG342 leads to broad changes in the MM surface proteome including decrease in expression of BCMA (Fig. B). Lastly, we employed pSILAC mass spectrometry to profile JG342 mediated changes in protein synthesis and degradation. Calculated protein half-lives revealed a distinct subset of differentially regulated proteins after Hsp70 inhibition including aminotransferases and DNA chaperones. Conclusions: Inhibition of Hsp70 is a promising therapeutic strategy to overcome PI resistance in myeloma, but new molecules with more favorable in vivo properties are needed to benefit patients. The "JG" molecules also provide a novel set of tool compounds for exploring protein homeostasis biology not only in MM but across biological systems.